Tumor proximity to serosal surface as an independent prognostic factor in stage I endometrial cancer

2019 ◽  
Vol 154 ◽  
pp. 259-260
Author(s):  
L.M. Harbin ◽  
L.K. Berry ◽  
E. Green ◽  
A. Wahlquist ◽  
W.A. Graybill
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factor ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Serosal Surface

Transection of vaginal cuff is an independent prognostic factor in stage I endometrial cancer

2008 ◽  
Vol 34 (2) ◽  
pp. 241-246 ◽  
Author(s):  
H. Arndt-Miercke ◽  
A. Martin ◽  
V. Briese ◽  
R. Fietkau ◽  
B. Gerber ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factor ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Vaginal Cuff

Is Peritoneal Cytology an Independent Prognostic Factor in Early-Stage Endometrial Cancer?

2021 ◽  
Vol 19 (2) ◽  
Author(s):  
A. K. Padhy ◽  
Mahapatra Manoranjan ◽  
Mishra Jagannath ◽  
Subhashree Rout ◽  
Mohapatra Janmejay ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factor ◽  
Early Stage ◽  
Independent Prognostic Factor ◽  
Peritoneal Cytology ◽  
Early Stage Endometrial Cancer

Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma

2006 ◽  
Vol 24 (34) ◽  
pp. 5414-5418 ◽  
Author(s):  
Sing-fai Leung ◽  
Benny Zee ◽  
Brigette B. Ma ◽  
Edwin P. Hui ◽  
Frankie Mo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Early Stage ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Ebv Dna ◽  
Epstein Barr

Purpose To evaluate the effect of combining circulating Epstein-Barr viral (EBV) DNA load data with TNM staging data in pretherapy prognostication of nasopharyngeal carcinoma (NPC). Patients and Methods Three hundred seventy-six patients with all stages of NPC were studied. Pretreatment plasma/serum EBV DNA concentrations were quantified by a polymerase chain reaction assay. Determinants of overall survival were assessed by multivariate analysis. Survival probabilities of patient groups, segregated by clinical stage (I, II, III, or IV) alone and also according to EBV DNA load (low or high), were compared. Results Pretherapy circulating EBV DNA load is an independent prognostic factor for overall survival in NPC. Patients with early-stage disease were segregated by EBV DNA levels into a poor-risk subgroup with survival similar to that of stage III disease and a good-risk subgroup with survival similar to stage I disease. Conclusion Pretherapy circulating EBV DNA load is an independent prognostic factor to International Union Against Cancer (UICC) staging in NPC. Combined interpretation of EBV DNA data with UICC staging data leads to alteration of risk definition of patient subsets, with improved risk discrimination in early-stage disease. Validation studies are awaited.

Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma

2006 ◽  
Vol 24 (5) ◽  
pp. 798-804 ◽  
Author(s):  
Henrik Schmidt ◽  
Julia S. Johansen ◽  
Pia Sjoegren ◽  
Ib J. Christensen ◽  
Boe S. Sorensen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Serum Level ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Serum Samples ◽  
Primary Tumor Site ◽  
Ajcc Stage ◽  
American Joint Committee

PurposeTo evaluate the novel tumor biomarker YKL-40 in serial serum samples from patients with American Joint Committee on Cancer (AJCC) stage I and II melanoma from the time of diagnosis and during routine follow-up. Macrophages, neutrophils, and cancer cells secrete YKL-40, and a high serum level has been associated with poor prognosis in patients with several cancer types.Patients and MethodsSerum samples from 234 patients with stage I (n = 162) and II (n = 72) melanoma were analyzed for YKL-40 by enzyme-linked immunosorbent assay. Serial samples were obtained before definitive primary surgery and during follow-up.ResultsAfter a median follow-up period of 66 months (range, 1 to 97 months), 41 relapses (18%) and 39 deaths (17%) were observed. Serum YKL-40 treated as an updated continuous covariate were analyzed together with the covariates sex, age, primary tumor site, ulceration, thickness, Clark level and histologic subtype in a Cox proportional hazard model. Serum YKL-40 was an independent prognostic factor of relapse-free survival (hazard ratio [HR], 1.6; 95% CI, 1.1 to 2.5; P = .03) and overall survival (HR, 1.8; 95% CI, 1.2 to 2.6; P = .002) together with thickness and ulceration. The serum level of YKL-40 (dichotomized as normal or elevated) at the time of diagnosis was also an independent prognostic factor for overall survival (HR, 3.6, 95% CI, 1.7 to 7.7; P = .001).ConclusionSerum YKL-40 may be an early biomarker of relapse and survival in patients with AJCC stage I and II melanoma. Serum YKL-40 may also be useful for patient stratification and follow-up in clinical trials. Our results need confirmation in an independent study.

Analysis of Patients With Stage IIIC Endometrial Cancer

2014 ◽  
Vol 24 (6) ◽  
pp. 1033-1041 ◽  
Author(s):  
Taner Turan ◽  
Isin Ureyen ◽  
Ipek Duzguner ◽  
Enis Ozkaya ◽  
Tolga Tasci ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factor ◽  
Lymph Nodes ◽  
Univariate Analysis ◽  
Independent Prognostic Factor ◽  
Stage Iiic ◽  
Metastatic Lymph Nodes ◽  
Systematic Lymphadenectomy ◽  
Metastatic Lymph ◽  
Gynecology And Obstetrics

ObjectiveWe aimed to define the factors that are related to recurrence and survival in patients with stage IIIC endometrial carcinoma in this study.Materials and MethodsA total of 147 patients who underwent staging surgery and had a diagnosis of stage IIIC1 to IIIC2 endometrial cancer according to the International Federation of Gynecology and Obstetrics 2009 were included. Patients whose data could not be obtained and patients with a diagnosis of uterine sarcoma and with synchronous tumors were excluded.ResultsMean age of the patients was 58.6 years. Among these patients, 63 had stage IIIC1 and 84 had stage IIIC2 disease. Extrauterine spread was detected in 22% of the patients. Median number of paraaortic (PA) and pelvic lymph nodes removed were 16.5 and 38, respectively. Paraaortic and pelvic nodal involvements were detected in 84 patients and 125 patients, respectively. Radiotherapy was applied more commonly as an adjuvant therapy. Three-year progression-free survival (PFS) and 3-year disease-specific survival (DSS) were 65% and 84%, respectively. Seventy percent of the recurrences were outside the pelvis. Site of metastatic lymph nodes and the number of metastatic PA lymph nodes were associated with 3-year PFS and lymphovascular space invasion; site of metastatic lymph nodes and the presence of recurrence were associated with 3-year DSS in the univariate analysis. Although any surgicopathological factor was not related to 3-year PFS, only the presence of recurrence was an independent prognostic factor for a 3-year DSS in the multivariate analysis (hazard ratio, 0.017; 95% confidence interval, 0.002–0.183).ConclusionsThe number of debulked metastatic lymph nodes and PA involvement were associated with recurrence in the univariate analysis. The presence of recurrence was the only independent prognostic factor detecting survival. Therefore, systematic lymphadenectomy involving PA lymph nodes instead of sampling should be performed in patients with high risk for nodal involvement in endometrial cancer.

Sign in / Sign up

Export Citation Format

Share Document